ER-positive breast cancers, which constitute the majority of hormone receptor-positive cases, are typically treated with selective estrogen receptor modulators (e.g., tamoxifen) or aromatase inhibitors to inhibit estrogen-driven tumor growth. Here, NR4A1 is linked to neoplasm.